COVID-19 therapy, from lung disease to systemic disorder.
作者信息
Pitchford Simon, Zanella Isabella
机构信息
King's College London, London, United Kingdom.
University of Brescia, Department of Molecular and Translational Medicine, Brescia, Italy.
出版信息
Curr Res Pharmacol Drug Discov. 2022;3:100099. doi: 10.1016/j.crphar.2022.100099. Epub 2022 Apr 1.
Abstract
摘要
相似文献
1
COVID-19 therapy, from lung disease to systemic disorder.新冠病毒疾病治疗：从肺部疾病到全身性疾病
Curr Res Pharmacol Drug Discov. 2022;3:100099. doi: 10.1016/j.crphar.2022.100099. Epub 2022 Apr 1.
2
Immunomodulatory and Anti-fibrotic Effects Following the Infusion of Umbilical Cord Mesenchymal Stromal Cells in a Critically Ill Patient With COVID-19 Presenting Lung Fibrosis: A Case Report.在一名患有肺纤维化的新冠肺炎危重症患者中输注脐带间充质基质细胞后的免疫调节和抗纤维化作用：一例报告
Front Med (Lausanne). 2021 Nov 17;8:767291. doi: 10.3389/fmed.2021.767291. eCollection 2021.
3
Lung and kidney perfusion deficits diagnosed by dual-energy computed tomography in patients with COVID-19-related systemic microangiopathy.COVID-19 相关系统性微血管病患者的双能 CT 诊断肺和肾灌注不足。
Eur Radiol. 2021 Feb;31(2):1090-1099. doi: 10.1007/s00330-020-07155-3. Epub 2020 Aug 29.
4
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments.Covid-19 与风湿免疫性系统性疾病：预先存在肺部受累和正在进行的治疗的作用。
Curr Pharm Des. 2021;27(41):4245-4252. doi: 10.2174/1381612827666210903103935.
5
Association between cytokine profiles and lung injury in COVID-19 pneumonia.新型冠状病毒肺炎肺炎中细胞因子谱与肺损伤的关系。
Respir Res. 2020 Jul 29;21(1):201. doi: 10.1186/s12931-020-01465-2.
6
The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19.胸部 CT 在解读肺间质受累中的作用：系统性硬化症与 COVID-19。
Rheumatology (Oxford). 2022 Apr 11;61(4):1600-1609. doi: 10.1093/rheumatology/keab615.
7
Evaluation of the susceptibility and fatality of lung cancer patients towards the COVID-19 infection: A systemic approach through analyzing the ACE2, CXCL10 and their co-expressed genes.肺癌患者对新型冠状病毒肺炎感染的易感性和致死率评估：通过分析血管紧张素转换酶2、CXC趋化因子配体10及其共表达基因的系统方法
Curr Res Microb Sci. 2021 Dec;2:100022. doi: 10.1016/j.crmicr.2021.100022. Epub 2021 Feb 9.
8
Combination of acute exacerbation of idiopathic nonspecific interstitial pneumonia and pulmonary embolism after booster anti-COVID-19 vaccination.新冠疫苗加强针接种后特发性非特异性间质性肺炎急性加重与肺栓塞并存
Respir Med Case Rep. 2022 May 24;38:101674. doi: 10.1016/j.rmcr.2022.101674. eCollection 2022.
9
Impact of COVID-19 outbreak in an Italian cohort of patients with systemic sclerosis.新冠疫情对意大利一组系统性硬化症患者的影响。
Ther Adv Musculoskelet Dis. 2020 Sep 24;12:1759720X20953356. doi: 10.1177/1759720X20953356. eCollection 2020.
10
Immune Immunomodulation in Coronavirus Disease 2019 (COVID-19): Strategic Considerations for Personalized Therapeutic Intervention.新型冠状病毒病 2019（COVID-19）中的免疫免疫调节：个性化治疗干预的策略考虑。
Clin Infect Dis. 2022 Jan 7;74(1):144-148. doi: 10.1093/cid/ciaa904.
本文引用的文献
1
Therapeutics for COVID-19 and post COVID-19 complications: An update.新型冠状病毒肺炎及其后遗症的治疗：最新进展
Curr Res Pharmacol Drug Discov. 2022;3:100086. doi: 10.1016/j.crphar.2022.100086. Epub 2022 Feb 4.
2
Strategies for drug repurposing against coronavirus targets.针对冠状病毒靶点的药物重新利用策略。
Curr Res Pharmacol Drug Discov. 2022;3:100072. doi: 10.1016/j.crphar.2021.100072. Epub 2021 Dec 4.
3
Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19.作用于Toll样受体（TLR）7和/或TLR8的药物制剂在2019冠状病毒病（COVID-19）中的潜在价值
Curr Res Pharmacol Drug Discov. 2021;2:100068. doi: 10.1016/j.crphar.2021.100068. Epub 2021 Nov 2.
4
Potential inhibitors of SARS-CoV-2 (COVID 19) spike protein of the delta and delta plus variant: In silico studies of medicinal plants of North-East India.新冠病毒（COVID-19）德尔塔及德尔塔plus变异株刺突蛋白的潜在抑制剂：印度东北部药用植物的计算机模拟研究
Curr Res Pharmacol Drug Discov. 2021;2:100065. doi: 10.1016/j.crphar.2021.100065. Epub 2021 Oct 22.
5
The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response.针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的生物制剂的研发：免疫反应较差患者群体中抗体的治疗潜力。
Curr Res Pharmacol Drug Discov. 2021;2:100064. doi: 10.1016/j.crphar.2021.100064. Epub 2021 Oct 9.
6
An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19.关于新型冠状病毒肺炎潜在治疗药物候选物、疫苗的最新综述以及对已提交专利的见解。
Curr Res Pharmacol Drug Discov. 2021;2:100063. doi: 10.1016/j.crphar.2021.100063. Epub 2021 Oct 8.
7
Can the application of graphene oxide contribute to the fight against COVID-19? Antiviral activity, diagnosis and prevention.氧化石墨烯的应用能否助力抗击新冠疫情？抗病毒活性、诊断与预防。
Curr Res Pharmacol Drug Discov. 2021;2:100062. doi: 10.1016/j.crphar.2021.100062. Epub 2021 Oct 5.
8
Host directed therapies: COVID-19 and beyond.宿主导向疗法：新冠疫情及未来
Curr Res Pharmacol Drug Discov. 2021;2:100058. doi: 10.1016/j.crphar.2021.100058. Epub 2021 Sep 25.
9
Recent progress in the development of potential drugs against SARS-CoV-2.抗新型冠状病毒潜在药物研发的最新进展。
Curr Res Pharmacol Drug Discov. 2021;2:100057. doi: 10.1016/j.crphar.2021.100057. Epub 2021 Sep 14.
10
Physiopathology and prospectives for therapeutic treatment of pulmonary fibrotic state in COVID-19 patients.COVID-19患者肺纤维化状态的病理生理学及治疗前景
Curr Res Pharmacol Drug Discov. 2021;2:100056. doi: 10.1016/j.crphar.2021.100056. Epub 2021 Sep 16.
Zotero 插件